Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
Here’s what happened last week in the GLP1 ecosystem: 📑 Orforglipron Phase 3 trial results landed 📢 TEVA Pharmaceuticals announced FDA approval for weight loss with Liraglutide 🎤 Meghan Trainor has been in the news after a GLP1 transformation 🎾 Serena Williams has shared her GLP1 story Go deeper, read more Here are
drug:orforglipron
We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly
drug:cagrisema
We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s
chemical:semaglutide
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
drug:mounjaro
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
politics
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
drug:phentermine
Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?
chemical:semaglutide
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
company:hims
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:novo-nordisk
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
company:weight-watchers
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
drug:wegovy
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).